BioNTech (BNTX) Competitors

BioNTech (NASDAQ:BNTX) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Is BNTX or TAK a better dividend stock?

BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.7%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 3.2%. BioNTech pays out 306.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Takeda Pharmaceutical pays out 87.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Takeda Pharmaceutical is clearly the better dividend stock, given its higher yield and lower payout ratio.

Which has more volatility & risk, BNTX or TAK?

BioNTech has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Do insiders & institutionals hold more shares of BNTX or TAK?

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media prefer BNTX or TAK?

In the previous week, BioNTech had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 9 mentions for BioNTech and 3 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.82 beat BioNTech's score of 0.62 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor BNTX or TAK?

BioNTech received 24 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. However, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 44.13% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 124 44.13%	Underperform Votes 157 55.87%
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%

Which has stronger valuation & earnings, BNTX or TAK?

BioNTech has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.69B	7.95	$1.01B	$0.50	179.88
Takeda Pharmaceutical	$28.20B	1.67	$994.06M	$0.55	26.93

Do analysts rate BNTX or TAK?

BioNTech presently has a consensus target price of $109.09, suggesting a potential upside of 21.29%. Given BioNTech's higher probable upside, equities analysts plainly believe BioNTech is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.50
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Is BNTX or TAK more profitable?

Takeda Pharmaceutical has a net margin of 6.02% compared to BioNTech's net margin of -18.69%. Takeda Pharmaceutical's return on equity of 10.11% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-18.69%	-2.54%	-2.24%
Takeda Pharmaceutical	6.02%	10.11%	4.83%

Summary

BioNTech and Takeda Pharmaceutical tied by winning 10 of the 20 factors compared between the two stocks.